Dr Max Crispin
Dr Max Crispin runs the Glycoprotein Therapeutics Laboratory within the Oxford Glycobiology Institute. He read Biochemistry at the University of Oxford before completing a joint doctorate between the Oxford Glycobiology institute and The Scripps Research Institute in California. After post-doctoral work on the structural biology of therapeutic antibodies in the Division of Structural Biology at Oxford he joined the Oxford Glycobiology Institute and has led a research team since 2013. He is a Lecturer at Corpus Christi College and the Against Breast Cancer Fellow at Oriel College
Dr Stephen Beers
Dr Stephen Beers is Associate Professor in Cancer Immunology and Immunotherapy within Medicine at the University of Southampton
Stephen Beers joined the University of Southampton, Faculty of Medicine in 2002. He leads a research group in the Centre for Cancer Immunology studying antibody immunotherapy drugs and their mechanisms of action. The Beers’ group focuses on understanding the role of host factors such as obesity, nutrition and the tumour microenvironment in helping cancers turn off the patients’ immune system so that the cancer can grow and avoid eradication with treatment. The group aims through uncovering host derived immune resistance mechanisms to improve existing immunotherapies and develop new strategies and drugs to enhance patient responses.
Dr Charles Birts
Postdoctoral Researcher & Lecturer
Dr Charles Birts has been researching breast cancer biology for over 11 years. As a postdoctoral researcher at the University of Southampton his research focused on the molecular mechanisms driving breast cancer. In 2014 he was awarded a Career Track Research Fellowship by the University allowing him to develop his own independent research in the area of cancer cell metabolism. This led to a European Society of Clinical Nutrition and Metabolism fellowship investigating the effect of metabolic and immunologic targeting on breast cancer development. He is now an Against Breast Cancer funded lecturer at the University of Southampton. He aims to develop new antibody-based therapies and investigate the effect of diet and lifestyle on breast cancer development and therapy. Dr Birts starts in August 2018.
Dr John Butler
Dr John Butler did his degree in Biochemistry followed by a PhD in Molecular Biology at Southampton University. This focussed mainly on cellular transport and targeting of membrane proteins. In 2018 he joined the Glycoprotein Therapeutics Laboratory at Southampton University under Professor Max Crispin’s guidance to aid in the production and engineering of glycoproteins such as antibodies. Dr Butler also provides day-to-day management of the laboratory.
ABC/Cisco Doctoral student
Hannah studied Biomedical Science with Professional Placement at the University of Bath. She will commence her doctoral studies under the supervision of Prof. Max Crispin and Dr Steven Beers in October. Her project will entail adapting the antibody effector function of therapeutic antibodies with the aim of improving therapy for the treatment of secondary breast cancer. Her post is funded by Against Breast Cancer following generous support from Cisco.
Dr Oliver Pearce
Dr Pearce has a multidisciplinary training in organic chemistry, immunology and cancer biology. After his degree he took a position with the pharmaceutical company Merck Sharp & Dohme (MSD). Two years later he moved to Oxford University to pursue a PhD in organic chemistry where he specialized in carbohydrate chemistry with application to targeting viral gene vectors for cancer therapy. For his post-doctoral studies he moved to the University of California where he investigated the role of glycans in human immunity and in particular cancer immunity and ‘inflamm-aging’. After five years he returned to the UK for a second post-doc position at Barts Cancer Institute (BCI). In September 2017 he was promoted to lecturer at the BCI and started his own research program. The focus of his research is the tumour microenvironment (TME), including how it forms, supports tumour progression, and inhibits host immunity. He is particularly interested in understanding the composition and function of the tumour extracellular matrix in generating an immunosuppressed environment.
Dr Weston Struwe
Dr Weston has worked in the Department of Chemistry in Oxford since 2012. His research exploits mass spectrometry, a technique capable of detailing the mass, size and shape of biomolecules, to understand the importance of protein glycosylation in human development, pathogenic diseases and in biotherapeutic drug design. Weston has published over 30 papers in the field of glycobiology and mass spectrometry and is a Research Scholar at University College, Oxford.
Dr Miriam Dwek
Principal Investigator and Senior Lecturer in Biochemistry
Miriam is a cancer biologist and joined the University of Westminster in 2002, establishing the Cancer Glycobiology Laboratory. Prior to this Miriam read her PhD and undertook Post Doctoral Studies in the Medical School at UCL with the charity founder Dr Anthony Leathem. Miriam is responsible for bringing in and leading the Against Breast Cancer Unit.
Dr Claire Robertson
Senior Lecturer in Nutrition
Claire is a nutritionist and epidemiologist who has worked on the INTERMAP project – a worldwide study of heart disease and dietary intake. Claire offers support to the members of the Diet & Lifestyle team.
Dr Anthony Leathem
Charity founder and principal adviser
Thirty years ago Anthony was a pathologist at Middlesex Hospital – later University College London (UCL). Disturbed by the number of post mortems he carried out on young women with breast cancer, he has since devoted his life to improving breast cancer survival. Anthony retired from his post as Head of the Breast Cancer Research Group at UCL in 2009 and currently holds an Honorary Senior Lecturership. He remains actively involved as an advisor to the group.
Dr Ruth Swann
Study Coordinator - Diet Group Leader
Ruth is responsible for the day-to-day management of the Diet & Lifestyle study, coordinating sample collection, sample movement, ensuring quality control assessment, integrity of data entry and outputs from the study.
Clinical researcher and database programmer
Annie is involved with patient recruitment to the Diet & Lifestyle study and takes a lead in querying the databases for subsequent data analysis.
Dr Babak Afrough
Babak is studying changes in the sugars attached to proteins (often found increased in cancer tissue samples) using naturally occurring carbohydrate binding proteins (lectins) and antibodies from cancer patients. The aim is to identify cancer proteins that might later be targeted in treatment strategies.
Simon’s work is focussed on human serum; this fraction of human blood contains thousands of different proteins. The aim of the work is to identify proteins in the serum which may serve as markers of the presence of breast cancer and may be useful for monitoring response to treatment.
Dr Hannah Lomax-Browne
Hannah’s work concentrates on immunoglobulin A and in particular on the sugars attached to this protein as this may serve as a marker for both breast cancer and breast cancer progression.
Dr Diluka Peiris
Diluka is studying proteins from breast cancer tissue samples of patients with secondary cancers in the axillary lymph nodes. The aim of the work is to identify proteins associated with the spread of cancer beyond the breast to secondary organs (metastasis).
Dr Ingunn Holen
Professor of Bone Oncology
Dr Ingunn Holen is Professor of Bone Oncology and team leader in the Department of Oncology and Metabolism, University of Sheffield, UK where she also is science lead of the Sheffield Experimental Cancer Medicine Centre. Prof Holen has more than 20 years experience in working in advanced breast cancer, in particular in the context of translational studies in metastatic bone disease. She has published 120+ scientific papers with more than 5,000 citations and is a frequently keynote speaker at international scientific conferences. Working in collaboration with colleagues across the world, her team has studied the effects of combining anti-cancer agents (targeting the tumour cells) with compounds that target the bone microenvironment. The Holen team has also established a range of complex model systems for studies of tumour growth in bone, including detection of single disseminated tumour cells in skeletal niches. Her Against Breast Cancer project is focussed on elucidating the biological mechanisms supporting tumour cell dormancy in bone, in order to identify novel therapeutic targets in metastatic breast cancer